8d ago

avatar

Spring Health

Senior Director, Quality Engineering

$230K - $250K

New York, NY

Senior (10+ years)

Healthcare

Enterprise (1000+)

[object Object],[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object], ,[object Object],[object Object],[object Object]

Questions about the Senior Director, Quality Engineering role at Spring Health

How do you measure the ROI of AI-driven quality initiatives and agent adoption?

To measure the ROI of AI-driven quality initiatives and agent adoption, I focus on balancing engineering productivity with release confidence. Key performance indicators include:

  • Productivity Metrics: Tracking reductions in test cycle time, automation maintenance effort, and developer velocity (time from code commit to production).
  • Quality Metrics: Monitoring the escaped defect rate, change failure rate, and mean time to recovery (MTTR).
  • AI-Specific Evals: Quantifying the performance of autonomous agents via eval pass rates, model accuracy (e.g., LLM-as-judge scores), and the cost-efficiency of automated triage compared to manual QA efforts.

Ultimately, ROI is realized when AI agents reduce operational overhead, provide faster feedback loops, and increase release frequency without compromising critical compliance and clinical safety standards.

What are the biggest challenges in balancing release speed with LLM reliability?

The biggest challenge in balancing release speed with LLM reliability lies in the inherent non-deterministic nature of AI. Unlike traditional software, LLM outputs lack fixed expected values, making standard regression testing insufficient. You must implement robust "AI-as-judge" evaluation harnesses, golden datasets, and red-teaming protocols to ensure safety and accuracy without creating manual bottlenecks.

Furthermore, maintaining speed requires transitioning from human-led validation to autonomous, agentic testing frameworks that can monitor model drift and prompt regressions in real-time. The goal is to build an infrastructure where clinical trust, regulatory compliance (HIPAA/SOC 2), and responsible AI guardrails are embedded into the SDLC, allowing engineers to release with confidence rather than slowing down for traditional quality gates.

How is the industry shifting from manual QA to autonomous engineer-owned quality?

The industry is shifting from traditional, manual gatekeeping toward a "shift-left" model where quality is integrated directly into the software development lifecycle. Instead of relying on centralized QA teams for final validation, engineering teams now own quality outcomes through "quality-by-design" principles. This transition is powered by autonomous agents that handle repetitive tasks like test generation, regression, and defect analysis, allowing engineers to release faster with higher confidence. By embedding automated evaluation frameworks and AI-driven insights directly into CI/CD pipelines, organizations move away from slow, manual processes toward scalable, intelligent systems. This evolution empowers developers to maintain high standards of reliability, security, and compliance while accelerating product innovation.

How does the clinical team integrate with QE to ensure AI safety and compliance?

The clinical team serves as a critical partner to the Quality Engineering (QE) organization, ensuring that AI-driven features meet rigorous safety, regulatory, and ethical standards. QE collaborates closely with Clinical, Security, and Privacy teams to embed compliance directly into the software development lifecycle. This integration involves establishing robust validation frameworks that guarantee the reliability and accuracy of LLM-powered workflows. By co-developing guardrails, red-teaming protocols, and evaluation systems, the teams ensure that AI outputs are clinically sound, HIPAA-compliant, and trustworthy. Clinical stakeholders help define the benchmarks for safe performance, allowing QE to provide the necessary evidence, auditability, and traceability required for high-consequence healthcare environments while supporting responsible AI deployment across the platform.

How will this role shape the future of our AI-native engineering culture?

This Senior Director role is central to institutionalizing a "quality-by-design" culture at Spring Health. You will transition the engineering organization from manual, reactive testing to a proactive, AI-augmented model. By implementing autonomous testing agents, LLM-as-a-judge frameworks, and robust evaluation infrastructure, you will empower engineering teams to own quality outcomes directly. Your leadership will move the focus beyond simple validation, embedding rigor into the full AI-native SDLC. By establishing clear standards for trust, safety, and responsible AI, you will ensure that rapid innovation never sacrifices clinical integrity. Ultimately, you will redefine engineering excellence, positioning quality as a strategic enabler that accelerates delivery while guaranteeing the reliability and safety of life-changing mental health care.